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Abstract
Colorectal cancer (CRC) is one of the most common malignant tumours in
Poland. Annually approximately 11 000 new cases of CRC are diagnosed, while
the number of deaths caused by CRC approaches 8 000. Five-year survival does
not exceed 20%. Familial adenomatous polyposis (FAP) is responsible for about
1% of new cases of CRC. The risk of CRC in FAP syndrome is 100%, and the
average age of CRC development is 39 years. Early colectomy is the most
effective method of CRC prevention. We report an atypical case of CRC in
a patient with FAP caused by 2797-2800delAACA mutation of the APC gene.
Key words: colorectal cancer, APC gene, FAP syndrome, adjuvant chemotherapy,
colectomy, follow-up.
Introduction
Colorectal cancer is one of the most common malignant tumours.
Annually approximately 11 000 new cases of CRC are diagnosed in Poland,
while the number of deaths caused by CRC approaches 8 000. Five-year
survival does not exceed 20%. The majority of colorectal cancers originate
from adenomas. The risk of malignant transformation of a benign lesion
is approximately 2% annually. Large polyps, of at least 10 mm diameter,
villous polyps and polyps with a high degree of dysplasia are at high risk
of malignant transformation [1-4].
Gastrointestinal malignancies have a significant genetic background.
Hereditary non-polyposis colorectal cancer (HNPCC) (accounts for
approximately 10% of cases of colorectal cancer) and familial adenomatous
polyposis syndrome (FAP) (1% of all colorectal cancer cases) are associated
with hereditary high penetration mutations in DNA repair and tumour
suppressor genes, respectively.
Familial adenomatous polyposis is caused by mutations of the
suppressor gene APC (adenomatous polyposis coli – incidence 1/7500 
– 1/10 000 in the general population) [5]. Familial adenomatous polyposis
predisposes towards multiple polyps in the colon and rectum. The polyps
appear starting from the second decade of life and undergo malignant
transformation if untreated. The average age of tumour development in
a FAP patient is 39 years. The risk of malignancy in FAP is essentially 100%.
Total colectomy is the best management that minimizes the risk of
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colorectal cancer (when the rectum is left intact,
there is a risk of rectal cancer) [6-8]. Polyps in the
upper gastrointestinal tract are observed in 
such patients as well as non-gastrointestinal
malignancies such as tumours of the thyroid and
brain and desmoid tumours.
Hereditary mutations of the APC gene usually
result in loss of function of one of the alleles. Small
mutations, involving 1 to a few nucleotides, as well
as larger mutations, involving respective exons or
the whole APC gene, have been observed. The
majority of APC  gene mutations have been
observed in the 5’ part of exon 15 of the APC gene
[9, 10]. These mutations are associated with classic
FAP form. Mutations of the initial gene sequence
to exon 4, exon 9 and the 3’ part of exon 15 are
associated with milder disease course referred 
to as attenuated adenomatous polyposis coli 
(AAPC) [11].
We present an atypical case of colorectal cancer
in the course of FAP associated with “de novo”
mutation of the APC gene, review literature related
to FAP and provide genetic commentary.
Case report
A 25-year old female patient with cancer of the
sigmoid colon was admitted to the Clinic of
Oncology, Military Medical Institute in Warsaw, in
February 2007, to undergo adjuvant chemotherapy.
On 1 January 2007 the patient was admitted to
the Department of General Surgery with symptoms
of subileus. Colonoscopy demonstrated a very large
number of sitting and pedicular polyps, with
diameter of 0.4 cm to 1.2 cm. Gastroscopy was
unremarkable. Computed tomography imaging of
the abdominal cavity and pelvis demonstrated
intestinal obstruction and trace amounts of fluid in
the Douglas cavity. She underwent a surgical
operation on 13.01.2007 due to intestinal
obstruction: her sigmoid colon was resected and
permanent colostomy was performed.
Pathological evaluation:
– macroscopic: a fragment of the large intestine
10 cm in length; a tumour completely obstructing
the intestinal lumen is located 1 cm and 4 cm
from the margins of surgical section;
– microscopic: moderately differentiated adeno-
carcinoma (mucosal adenocarcinoma G2),
infiltrating the full thickness of the intestinal wall
and peri-intestinal fat tissue (T3) and metastases
in the lymph nodes (2/9 lymph nodes with
metastases – N1). The final diagnosis: pT3N1Mx
– Aster – Coller C2 (TNM classification stage IIIB)
[12, 13].
After the result was obtained, the patient was
referred to the Clinic of Oncology of the Medical
Military Institute in Warsaw to undergo further
therapy. Due to associated adverse prognostic
factors in the postoperative pathological
examination (infiltration of the full thickness of the
intestinal wall with infiltration of the peri-intestinal
fat tissue, metastases in the lymph nodes) and
intraoperative detection of a small amount of fluid
in the peritoneal cavity (the fluid was not taken for
cytological examination during the operation), the
patient was qualified for adjuvant chemotherapy
according to the regimen: oxaliplatin, 5-fluorouracil,
leucovorin (FOLFOX) at doses: 85 mg/m2 day 1, 
400 mg/m2 “bolus” day 1 and 2, and 600 mg/m2
day 1 and 2, 200 mg/m2 “bolus” day 1 and 2,
respectively.
The patient received a total of 12 cycles of
FOLFOX chemotherapy until August 2007. The
maximal toxicity observed during chemotherapy
was: grade 1 leucopenia, grade 1 neutropenia, 
grade 1 anaemia and grade 2 thrombocytopenia
according to common toxicity criteria (CTC) that
required 20% dose reduction (thrombocytopenia
required delays of subsequent chemotherapy
courses and thus after the 9th course the decision
was taken to reduce doses of chemotherapy).
Due to the genetic aetiology of FAP, the patient
was qualified for molecular testing of the APC gene
to possibly detect an APC gene mutation and subject
other members of her family to molecular testing.
Molecular analysis
DNA was extracted from the peripheral blood
cells using a phenol extraction method. The
encoding sequence of the APC gene was analysed
using the screening methods PCR-HD and PCR-
SSCP [14]. Additional conformers were observed in
the PCR-HD analysis of fragment C in exon 15
(Figure 1). This fragment was sequenced. Direct PCR
sequencing was performed using DYEnamic 
ET-Terminator (Amersham-Bioscience). The reaction
was performed according to the manufacturer’s
instructions. The product of the sequencing was
separated on an automatic Megabace 500
sequencing system. The results were analysed
using sequence analysis software (Amersham-
Bioscience). A mutation, 2797-2800delAACA, was
identified that shifted the reading frame and
formation of the STOP signal in codon 953 (Figure 2).
The detected mutation is a de novo mutation that
has not yet been reported in other populations.
Siblings of the proband did not have this mutation.
After completion of chemotherapy in September
2007, before a decision was made on further
treatment, follow-up imaging examinations were
performed: computed tomography imaging of the
abdomen and pelvis (which did not demonstrate
any lesions suspected of recurrence or dissemination
of the disease) and colonoscopy that confirmed
presence of multiple polyps in the large intestine;
the two most suspicious polyps were removed.Arch Med Sci 2, April / 2010 285
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Pathomorphological report:
– microscopic: polyp from the transverse colon –
tubular adenoma, resected completely; polyp from
the sigmoid colon – highly differentiated
adenocarcinoma, the cancer focus is on the top
of the adenoma, the section line is in the
unchanged mucosa.
Due to high risk of relapse of adenocarcinoma
in the remaining polyps of the large intestine and
in view of no recurrence or dissemination of the
disease in the imaging studies, a decision was taken
to proceed to surgical treatment after completion
of the adjunctive therapy. On 24.10.2007 the patient
underwent colectomy (the rectum was left intact
since no polyps were visualized in the rectum) in
the Clinic of Oncological Surgery and continuity of
the gastrointestinal tract was restored.
Pathomorphological report:
– macroscopic: large intestine with multiple polyps;
– microscopic: numerous polyps with evidence of
high degree dysplasia and two foci (in the
transverse colon and sigmoid colon) of highly
differentiated adenocarcinoma; no lymph node
involvement was found (0/10 lymph nodes).
According to the characteristics of FAP syndrome,
the follow-up assessments included: upper
gastrointestinal endoscopy every 24 months,
rectoscopy every 6-12 months and imaging studies
every 12 months until 5 years after completion of
the treatment (the last CT of the abdominal cavity
and pelvis was performed in March 2008; no
significant abnormalities were detected).
Discussion
Familial adenomatous polyposis (FAP) syndrome
is an autosomal dominant disorder. It is responsible
for 1% of cases of colorectal cancer. Its genetic
background substantiates the use of molecular
diagnosis, so that mutation carriers can be detected
long before they develop clinical symptoms that
make clinical diagnosis possible. The risk of
developing FAP in an APC gene mutation carrier is
essentially 100%. A screening programme should
be developed for such persons to detect the polyps
and then monitor them, to avoid cancer
development. Another advantage of such pro  -
grammes is that they alleviate constant stress in
individuals who are not mutation carriers, in whom
the cancer risk is as low as in the general
population. Radical surgical operation is largely
crippling but cannot be avoided. It is quite difficult
to determine when it should be performed. It is
a seriously crippling procedure should it not be
performed too early, because polyps in intestinal
polyposis take longer to develop cancer than with
HNPCC; however, too long delay may lead to cancer.
FAP is characterized by high variability. This
phenomenon is typical not only for carriers of the
same mutation but also for members of a single
family who also carry the same mutation [4].
Studies correlating genotype and phenotype have
been carried out for years and a pattern can be
observed. However, deviations that have been
observed from this pattern lead to the situation
that identification of a certain mutation and its
correlation with a specific disease course cannot
be the sole reason for therapeutic consequences.
The management and dates of possible procedures
must be determined on the basis of examinations
concerning a particular patient and they cannot be
used in other carriers of the same mutation due to
the variable course of the disease [12]. Some
authors suggest that phenotype inter-patient
variability with respect to various APC  gene
mutations can be explained by the proposed “just
Figure 1. PCR HD analysis of fragment C of exon 
15 of the APC gene
Arrow indicates additional conformers in patient no. 9355
occurring in association with 2797-2800delAACA286 Arch Med Sci 2, April / 2010
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right” signalling model related to abnormal
regulation of β-catenin levels. Proper accumulation
of β-catenin in the cell nucleus leads to activation
of transcription factor and promotes tumour growth
[15, 16]. According to some authors, colorectal
bleeding and frequent diarrhoea are the most
common specific (“intestinal”) symptoms related to
the large intestine polyps in this syndrome, while
“non-specific intestinal” symptoms include abdominal
pain and weight loss and weakening [6, 11].
The patient had no prior complaints that could
suggest multiple polyps that usually accompany FAP
syndrome. This could have been related to the polyp
size (the largest one measured 1.2 cm). Subileus
was its first symptom but was related to the
tumour obstructing the intestinal lumen rather than
the polyps themselves.
The presence of unfavourable prognostic factors
in the postoperative histopathological testing was
the reason for adjuvant chemotherapy given after
the first surgical procedure for intestinal obstruction.
These factors were associated with high probability
of disseminated disease. And so the surgical
procedure (prophylactic colectomy) was delayed until
the chemotherapy had been completed and disease
relapse and dissemination had been ruled out.
The prognosis in early FAP is favourable. The
patients can live for many years after a prophylactic
surgical procedure. Unfortunately, with time some
patients develop malignancies in other locations:
in the stomach, duodenum, small intestine, or
mesentery (desmoid tumours).
Oncological follow-up and endoscopic follow-up
of the upper gastrointestinal tract and rectoscopic
follow-up are very important in these patients. One
must not forget to perform genetic testing of close
family members (siblings, children, parents).
The longest follow-up reported in the available
literature is 18 years (on average 14 years). Eight
patients died out of the group of 110 patients (62
males and 48 females): 2 due to colorectal cancer
that developed prior to proctocolectomy, 2 due to
complications related to desmoid tumours, 2 due
to primary adenocarcinoma of the lung, 1 due to
complications during the first day after the
operation and 1 for reasons unrelated to APC or its
treatment. Fourteen patients were lost to follow-
up. APC mutation was detected in 50 families [17].
Our patient was diagnosed with colorectal
familial adenomatous polyposis and a pathogenic
APC gene mutation was identified in her. This
mutation is a novel mutation that has not been
previously reported in any population. Lack of
previous reports for this mutation and its de novo
occurrence in the family make it impossible to
compare the disease course. However, mutations
in this region of the APC gene usually cause the
classic form of colorectal polyposis. The reported
case is not different from this form of the disease.
Polyps could have appeared in the second decade
of the patient’s life or at its end. Their small size
did not cause mechanical intestinal dysfunction,
observed with larger polyps. What should be noted
is that the tumour developed out of only one of
multiple polyps, reaching a very large size. It is
difficult to speculate whether the tumour developed
from a polyp, or it was a sporadic tumour at
a young age. However, the latter are very rare. The
reported case may indicate that a variable rate of
tumour development occurs not only between
different patients, but also between different
tumours in the same patient [18]. Thus we can
conclude that prophylactic colectomy should be
considered in hereditary predisposition to
malignancies despite small polyps, due to the risk
that one of the polyps may undergo a rapid
malignant transformation.
Figure 2. Sequencing of fragment G of exon 15 of the APC gene
A – patient 9355. B – control. Arrow indicates the site of 2797-2800delAACA 
A
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